A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SEVELAMER CARBONATE TABLETS DOSED THREE TIMES A DAY IN HYPERPHOSPHATAEMIC CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS: